Posting study results isn't hype. most people who own the stock appreciate the information because you won't hear it from the company. The latest study may be the most significant yet: Controlled single-blinded study with a sham device with great results. It was published in May 5th in the Journal: NEUROLOGY
Scrambler therapy improves pain in
neuromyelitis optica
A randomized controlled trial
Maureen A. Mealy, PhD, RN, Sharon L. Kozachik, PhD, RN, FAAN, Lawrence J. Cook, PhD, Lauren Totonis, MSN,
Ruth Andrea Salazar, MD, Jerilyn K. Allen, ScD, RN, Marie T. Nolan, PhD, RN, FAAN, Thomas J. Smith, MD, and
Michael Levy, MD, PhD
Neurology® 2020;94:1-e8. doi:10.1212/WNL.0000000000009370
Abstract
Objective
To determine whether Scrambler therapy is an effective, acceptable, and feasible treatment of
persistent central neuropathic pain in patients with neuromyelitis optica spectrum disorder
(NMOSD) and to explore the effect of Scrambler therapy on co-occurring symptoms.
Methods
We conducted a randomized single-blind, sham-controlled trial in patients with NMOSD who
have central neuropathic pain using Scrambler therapy for 10 consecutive weekdays. Pain
severity, pain interference, anxiety, depression, and sleep disturbance were assessed at baseline,
at the end of treatment, and at the 30- and 60-day follow-up.
Results
Twenty-two patients (11 per arm) were enrolled in and completed this trial. The median
baseline numeric rating scale (NRS) pain score decreased from 5.0 to 1.5 after 10 days of
treatment with Scrambler therapy, whereas the median NRS score did not significantly decrease
in the sham arm. Depression was also reduced in the treatment arm, and anxiety was decreased
in a subset of patients who responded to treatment. These symptoms were not affected in the
sham arm. The safety profiles were similar between groups.
Conclusions
Scrambler therapy is an effective, feasible, and safe intervention for central neuropathic pain in
patients with NMOSD. Decreasing pain with Scrambler therapy may additionally improve
depression and anxiety.
Clinicaltrials.gov identifier
NCT03452176.
Classification of evidence
This study provides Class II evidence that Scrambler therapy significantly reduces pain in
patients with NMOSD and persistent central neuropathic pain.
